New stock news | The IPO prospectus of DeShi BioPort is invalid.
Hangzhou Deshi Biological Technology Co., Ltd. (referred to as Deshi Biology) submitted its Hong Kong stock prospectus on June 29 and it expired 6 months later on December 29.
Hangzhou Desheng Biological Technology Co., Ltd. (referred to as Desheng Biology) submitted its Hong Kong stock prospectus for 6 months on June 29 and expired on December 29. At the time of submission, Huatai International was the exclusive sponsor.
The prospectus shows that according to Frost & Sullivan data, iMedImageTM independently developed by Desheng Biology is the world's largest scale universal medical image pedestal model. It has been successfully commercialized and is recognized as the world's first commercial cross-modal medical image pedestal model.
Related Articles
BAIYING HOLDING (08525): Guan Lexin appointed as joint company secretary and authorized representative.
Bayzed Health (02609): Lv Chao appointed as President
WISON ENGRG(02236): Shi Donghui has been appointed as a member of the Audit Committee, Nomination Committee and Remuneration Committee respectively.
BAIYING HOLDING (08525): Guan Lexin appointed as joint company secretary and authorized representative.
Bayzed Health (02609): Lv Chao appointed as President
WISON ENGRG(02236): Shi Donghui has been appointed as a member of the Audit Committee, Nomination Committee and Remuneration Committee respectively.
